Lichen Planus Market

 Market Overview:

The 7 major lichen planus markets reached a value of US$ 91.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 139.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.95% during 2024-2034.

The lichen planus market has been comprehensively analyzed in IMARC's new report titled "Lichen Planus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lichen planus refers to a chronic inflammatory condition that mainly affects the skin, mucous membranes, hair, and nails. This disorder is characterized by the presence of itchy, flat-topped, polygonal-shaped papules or lesions that may appear shiny and reddish-purple in color. These lesions can occur anywhere on the body, but they commonly affect the wrists, ankles, lower back, and oral mucosa. The signs and symptoms of the ailment can vary depending on the impacted area. In the oral form of the condition, the lesions may cause pain or a burning sensation and can affect the inner lining of the cheeks, gums, tongue, and lips. When this illness develops on the scalp, it can lead to temporary or permanent hair loss among patients. Diagnosing lichen planus typically requires a combination of clinical features, a medical history assessment, and a physical test. The healthcare provider may also perform an allergy workup to determine the causes of underlying indications. In some cases, a skin biopsy may be utilized to validate a diagnosis among patients.

The increasing cases of autoimmune disorders, in which the body's defense system inadvertently attacks its own cells, are primarily driving the lichen planus market. Besides this, the rising prevalence of several associated risk factors, including viral infections, stress, use of certain medications, allergic reactions, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of effective drugs, such as corticosteroids, retinoids, immunosuppressive agents, etc., to relieve symptoms, alleviate inflammation, and promote healing is also bolstering the market growth. Additionally, the emerging popularity of stress management techniques, which can help to improve overall well-being, reduce the severity and frequency of lichen planus indications, and optimize immune functioning of patients, is creating a positive outlook for the market. Moreover, the inflating demand for phototherapy to modulate the immune response, leading to a decrease in inflammation and itching, is also augmenting the market growth. Apart from this, the increasing application of topical targeted therapy, owing to its various benefits, like lesion-specific treatment and enhanced patient compliance, is expected to drive the lichen planus market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the lichen planus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lichen planus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lichen planus market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the lichen planus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the lichen planus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lichen planus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the lichen planus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the lichen planus market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the lichen planus market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of lichen planus across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of lichen planus by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of lichen planus by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with lichen planus across the seven major markets?
• What is the size of the lichen planus patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of lichen planus?
• What will be the growth rate of patients across the seven major markets?
   

Lichen Planus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for lichen planus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lichen planus market?
• What are the key regulatory events related to the lichen planus market?
• What is the structure of clinical trial landscape by status related to the lichen planus market?
• What is the structure of clinical trial landscape by phase related to the lichen planus market?
• What is the structure of clinical trial landscape by route of administration related to the lichen planus market?